CVS HEALTH Corp (CVS) Form 8-K — Aug 5, 2026
CVS Health reported second quarter 2026 total revenues of $106.1 billion, up 7.3% year over year, with GAAP diluted EPS of $2.31 (up from $0.80) and Adjusted EPS of $2.58 (up from $1.81), driven primarily by continued execution of the Health Care Benefits margin recovery plan. The company raised full-year 2026 guidance across the board: GAAP diluted EPS to $6.84-$7.04 from $6.24-$6.44, Adjusted EPS to $7.90-$8.10 from $7.30-$7.50, and cash flow from operations to at least $11.5 billion from at least $9.5 billion. Management nonetheless retained a cautious view for the remainder of the year, citing elevated cost trends and potential macro headwinds.
Key figures
- Eps
- 2.31
- Revenue
- $106.1 billion
- Guidance
- FY2026 GAAP diluted EPS raised to $6.84-$7.04 (from $6.24-$6.44); Adjusted EPS raised to $7.90-$8.10 (from $7.30-$7.50); cash flow from operations raised to at least $11.5 billion (from at least $9.5 billion); full-year revenue projected at least $414.0 billion
- Net Income
- $2,995 million ($2,979 million attributable to CVS Health)
- Total Debt
- $61,410 million ($1,958 million current portion + $59,452 million long-term)
- Revenue Yoy
- +7.3%
- Total Assets
- $253,768 million
- Cash Position
- $11,329 million
- Adjusted EPS
- $2.58 (vs $1.81 prior year)
- Operating Income
- $4,703 million, up 97.5% YoY
- Days Claims Payable
- 41.7
- Medical Membership
- 26.0 million
- Medical Benefit Ratio
- 87.4% (vs 89.9% prior year)
- Operating Cash Flow YTD
- $10.6 billion
- Health Services Revenue
- $51,795 million, up 11.5% YoY
- Adjusted Operating Income
- $5,157 million, up 35.4% YoY
- Pharmacy Claims Processed
- 473.0 million
- Prescriptions Filled Growth
- 4.3% (30-day equivalent)
- Favorable Prior Year Development
- $1.2 billion (six months ended June 30, 2026)
- Pharmacy Consumer Wellness Adjusted OI
- $1,475 million, up 10.2% YoY
Price after filing
Close on the filing date to close N calendar days later (from $104.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.